FDA Grants De Novo Authorization To OMRON Healthcare For New Blood Pressure Monitors With AI-Powered Afib Detection Feature

(MENAFN- PR Newswire)

Advancing its Going for Zero mission, OMRON innovation makes AFib screening an integral part of the brand's routine home blood pressure monitoring experience

HOFFMAN ESTATES, Ill., Nov. 14, 2024 /PRNewswire/ --
In a pivotal stride to address the growing AFib epidemic, OMRON Healthcare today announced the U.S. Food and Drug Administration (FDA) has granted the company its De Novo authorization to market new home blood pressure monitors featuring breakthrough AI-powered atrial fibrillation detection. In a medical device first, OMRON's novel machine learning IntelliSenseTM AFib algorithm automatically analyzes the Pressure Pulse Wave generated during blood pressure measurement to detect AFib, a leading cause of stroke1.

OMRON IntelliSense AFib incorporates over 300 mathematical indices into a machine learning algorithm.

OMRON executives announced the De Novo authorization as the company prepares to participate in the American Heart Association Scientific Sessions in Chicago.

"OMRON Healthcare is making AFib screening a more integral part of our blood pressure monitoring experience as part of our Going for Zero mission to eliminate heart attack and stroke," said OMRON Healthcare President and CEO Ranndy Kellogg. "AFib is a serious condition that is under-discussed, under-checked and underdiagnosed. We want to change that."

"Our new AFib detection feature keeps closer watch on this high stroke risk condition during routine blood pressure monitoring, making AFib detection more widely accessible and more often practiced so we can help reduce the health risk," said Kellogg.

AFib is the most common type of heart arrythmia2. Left untreated, it increases risk of stroke, heart failure, myocardial infarction, chronic kidney disease, and dementia.

The FDA granted OMRON Healthcare medical-device authorization for the new AFib detection technology via the agency's De Novo classification3, a regulatory pathway for novel innovations for which there is no prior legally marketed device. The De Novo pathway is now being used by the FDA to review digital health products and medical devices that incorporate AI technologies4.

"OMRON invested in the De Novo pathway to affirm our commitment to medical-grade accuracy as we work to develop and introduce first-of-their-kind technologies," said Kellogg.

Built into OMRON blood pressure monitors, IntelliSenseTM
AFib – which incorporates over 300 mathematical indices into a machine learning algorithm – analyzes the Pressure Pulse Wave generated as the cuff inflates to detect disturbances specific to AFib with remarkable accuracy.

A clinical study published in the October 2024 Heart Rhythm Journal5 found that OMRON blood pressure monitors with IntellisenseTM
AFib demonstrated a sensitivity of 95 percent and a specificity of 98 percent for AFib detection. Clinical findings were initially presented at the Heart Rhythm Society Annual Meeting in May 2024.

Experts recognize AFib as a rapidly accelerating health epidemic6. While some AFib patients report experiencing heart palpitations, lightheadedness and extreme fatigue, approximately 40 percent are
asymptomatic, making it difficult to detect and diagnose the condition without regular screening.

The Journal of the American College of Cardiology7 published a study in September 2024 that found AFib is three times more prevalent than previously estimated. According to the American Stroke Association, millions of Americans with AFib are undiagnosed8. Risk factors for AFib include high blood pressure, obesity, diabetes, smoking, heavy use of alcohol, and sleep apnea9.

"High blood pressure affects more than half of all U.S. adults and is a top AFib risk factor. With this De Novo authorization, we are making it easy and routine for anyone with an IntellisenseTM
AFib-equipped OMRON blood pressure monitor to check for AFib," said Kellogg. "Ninety percent of heart attacks and strokes are preventable through regular blood pressure monitoring and behavior change10. Teaching those we serve how to monitor and act for better heart health is what Going for Zero is all about."

America's number one doctor and pharmacist recommended blood pressure monitor brand, OMRON will launch new upper arm blood pressure monitors with advanced AFib detection in the U.S. in early 2025.

About OMRON Healthcare, Inc.
OMRON Healthcare, Inc., is the world's leading manufacturer and distributor of personal heart health products and an innovator in technologies supporting respiratory and pain management care. With over 50 years of medical device category leadership, OMRON is passionate about empowering people to take charge of their health at home through precise technology. Its market-leading products include a full range of home blood pressure monitors, nebulizers and TENS devices. The company's mission is Going for Zero, the elimination of heart attacks and strokes. With more than 350 million devices sold globally, OMRON provides the world's most recommended blood pressure monitors by healthcare professionals. OMRON Healthcare strives to improve lives and contribute to a better society by developing innovations that help people prevent, treat, and manage their medical conditions. The company provides products and services in over 130 countries. For more information, visit OmronHealthcare .

1 CDC AFib and Stroke ://
2
CDC About Atrial Fibrillation ://
3 FDA De Novo
4 FDA De Novo AI First

5 Heart Rhythm Journal, October 2024


6
AHAIASA Journals
7 JACC study
8 American Stroke Association
9 NIH
10 Cleveland Clinic

SOURCE OMRON Healthcare

MENAFN14112024003732001241ID1108887344